Prime Medicine (PRME) Equity Ratio (2021 - 2025)
Prime Medicine (PRME) has disclosed Equity Ratio for 5 consecutive years, with 0.35 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio fell 31.49% year-over-year to 0.35, compared with a TTM value of 0.35 through Dec 2025, down 31.49%, and an annual FY2025 reading of 0.35, down 31.49% over the prior year.
- Equity Ratio was 0.35 for Q4 2025 at Prime Medicine, down from 0.42 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.88 in Q1 2023 and bottomed at 1.04 in Q3 2022.
- Average Equity Ratio over 5 years is 0.43, with a median of 0.57 recorded in 2024.
- The sharpest move saw Equity Ratio skyrocketed 269.58% in 2022, then plummeted 71.18% in 2025.
- Year by year, Equity Ratio stood at 0.52 in 2021, then surged by 269.58% to 0.88 in 2022, then decreased by 21.79% to 0.69 in 2023, then fell by 25.01% to 0.51 in 2024, then plummeted by 31.49% to 0.35 in 2025.
- Business Quant data shows Equity Ratio for PRME at 0.35 in Q4 2025, 0.42 in Q3 2025, and 0.22 in Q2 2025.